Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement

Pharmaceutical Research

Volumn 16, Issue 1, 1999, Pages 74-79

  Sjostrom M ^a   Lindfors, L ^a   Ungell, A L ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Absorption; Aprotinin; Peptide absorption; Permeability enhancement; Thrombin inhibitor

Indexed keywords

APROTININ; ENZYME INHIBITOR; INOGATRAN; PROTEINASE INHIBITOR; THROMBIN INHIBITOR; TRITIUM; TRYPSIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG TRANSPORT; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; ISOTOPE LABELING; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; APROTININ; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; GLYCINE; INTESTINAL ABSORPTION; MALE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; TRYPSIN INHIBITORS;

EID: 0032959834     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018870712463     Document Type: Article

References (19)

1. E. J. van Hoogdalem, A. G. De Boer, and D. D. Breimer. Intestinal drug absorption enhancement. An overview. Pharmac. Ther. 44:407-443 (1989).
2. S. Muranishi and A. Yamamoto. Mechanisms of absorption enhancement through gastrointestinal epithelium. In: Drug Absorption Enhancement, p. 67-100, ed A. G. De Boer, Harwood Academic Publishers (1994).
3. J. A. Fix. Strategies for delivery of peptides utilizing absorption-enhancing agents. J. Pharm. Sci. 85:1282-1285 (1996).
4. S. Fujii, T. Yokoyama, T. Ikegaya, F. Sato, and N. Yokoo. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol. 37:545-549 (1985).
5. V. H. L. Lee and A. Yamamoto. Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Delivery Rev. 4:171-207 (1989).
6. V. H. L. Lee., A. Yamamoto, and U. B. Kompella. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst. 8:91-192 (1991).
7. P. P. Constantinides, J.-P. Scalart, C. Lancaster, J. Marcello, G. Marks, H. Ellens, and P. Smith. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm. Res. 11:1385-1390 (1994).
8. H. L. Luessen, J. C. Verhoef, G. Borchard, C. -M. Lehr, A. G. De Boer, and H. E. Junginger. Mucoadhesive polymers in peroral peptide drug delivery II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. 12:1293-1298 (1995).
9. H. L. Luessen, B. J. de Leeuw, M. W. E. Langemeijer, A. G. De Boer, J. C. Verhoef, and H. E. Junginger. Mucoadhesive polymers in peroral drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13:1668-1672 (1996).
10. P. Lundin, S. Lundin, H. Olsson, B. Karlsson, B. Weström, and S. Pierzynowski. Enhanced intestinal absorption of oxytocin peptide analogues in the absence of pancreatic juice in pigs. Pharm. Res. 12:1478-1482 (1995).
11. U. Eriksson, L. Renberg, U. Bredberg, A.-C. Teger-Nilsson, and C.-G. Regårdh. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an anti-thrombotic drug. Biopharm. Drug Dispos. 19:55-64 (1998).
12. H. Lennernäs, S. Nylander, and A.-L. Ungell. Jejunal permeability: A comparison between the Ussing chamber technique and the Single-pass perfusion in humans. Pharm. Res. 14:667-671 (1997).
13. C. Smith, A. MacInnes, and M. J. Fowling. Abstract British society for haemostasis and Thrombosis Nordic Coagulation Group, 1-3, May, London (1996).
14. A.-L. Ungell, A. Andreasson, K. Lundin, and L. Utter. Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat. J. Pharm. Sci. 81:640-645 (1992).
15. K. Palm, K. Luhtman, A.-L. Ungell, G. Strandlund, and P. Artursson. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 85:32-39 (1996).
16. R. Griffiths, A. Lewis, and P. Jeffrey. Models of Drug Absorption in Situ and in Concious Animals. In: Models for Assessing Drug Absorption and Metabolism. Eds: R. T. Borchardt, P. L. Smith, and G. Wilson. Plenum press. (1996).
17. Chromogenix AB, Mölndal, Sweden: Determination of trypsin in duodenal fluid. Laboratory Instruction.
18. S. Gotoh, R. Nakamura, M. Nishiyama, T. Fujita, A. Yamamoto, and S. Muranishi. Does bacitracin have an absorption-enhancing effect in the intestine? Biol. & Pharmaceul. Bull. 18:794-796 (1995).
19. S. Gotoh, R. Nakamura, M. Nishiyama, Y.-S. Quan, T. Fujita, A. Yamamoto, and S. Muranishi. Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine. J. Pharm. Sci. 85:858-862 (1996).